Market Intelligence, Clinical Progress, and High-Purity Reagents for Rheumatoid Arthritis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for YWHAH drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | YWHAH Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for PPI screening. |
View YWHAH Products |
| Gene Delivery | YWHAH Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View YWHAH Products |
| Benchmark Ab | Anti-YWHAH Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and diagnostic assay development. |
View YWHAH Products |
| Validator | YWHAH siRNA Set For target knockdown verification and functional validation. |
View YWHAH Products |
| Related Target A | YWHAZ 14-3-3 family isoform zeta; critical for selectivity profiling and off-target screening. |
View YWHAZ Products |
| Related Target B | YWHAE 14-3-3 family isoform epsilon; co-implicated in neurological and oncological pathways. |
View YWHAE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Cross-Reactivity (14-3-3 family) | High-purity panels of YWHAH, YWHAZ, and YWHAE proteins strictly verified by mass spectrometry. |
| Protein-Protein Interaction (PPI) Assay Sensitivity | Theoretical MW verified, low-endotoxin recombinant proteins ensuring minimal assay interference. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live YWHAH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for YWHAH therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeted small-molecule inhibitors and molecular glues. As first-generation therapies and biomarkers reach the clinic, the next wave of R&D is targeting the specific disruption of YWHAH-mediated protein-protein interactions (PPI) in inflammatory joint diseases and oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Biotech Startups | Cancer, Neurodegeneration | Selectivity Assay (Need Mutant vs WT Proteins) |
| Diagnostics (ELISA/Lateral Flow) | Quest Diagnostics, Euroimmun | Rheumatoid Arthritis | High-purity antigen and positive control antibodies |
| Molecular Glues | Targeted Protein Degradation Firms | Solid Tumors | Ternary complex validation (Need stable recombinant proteins) |